Arcadia vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health and value-based care analytics platform aggregating clinical and claims data for health systems and ACOs. Burlington MA, raised $100M+.
About
Arcadia is a healthcare data and analytics company that helps health systems, ACOs, and payers succeed in value-based care arrangements. Headquartered in Burlington, Massachusetts, and having raised more than $100 million from investors including Andreessen Horowitz, Arcadia's platform aggregates clinical data from EHRs, claims data from payers, and social determinants of health data from community sources into a unified longitudinal patient record. This master data layer powers care management workflows, quality measurement, network analytics, and financial performance reporting for value-based care programs.\n\nArcadia's differentiation lies in its ability to normalize and harmonize data from dozens of disparate EHR and claims sources at scale, giving health system leaders and ACO operators a complete and accurate view of their attributed populations. The platform supports MSSP, Medicare Advantage, commercial value-based contracts, and Medicaid managed care programs, helping organizations track performance against quality metrics like HEDIS and CMS Stars while identifying high-risk members for intervention. Embedded care management tools allow clinical teams to act directly on the insights the platform surfaces.\n\nThe company has positioned itself as a strategic analytics partner for complex, multi-entity health systems that cannot rely on a single EHR vendor for population health insights. Arcadia competes with health IT giants like Health Catalyst and Optum as well as specialty vendors, and has continued to grow its customer base among large regional health systems and national provider organizations participating in risk-bearing contracts.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.